Lobentanzer, Sebastian https://orcid.org/0000-0003-3399-6695
Aloy, Patrick
Baumbach, Jan https://orcid.org/0000-0002-0282-0462
Bohar, Balazs
Carey, Vincent J.
Charoentong, Pornpimol
Danhauser, Katharina
Doğan, Tunca https://orcid.org/0000-0002-1298-9763
Dreo, Johann
Dunham, Ian
Farr, Elias https://orcid.org/0000-0002-4441-6513
Fernandez-Torras, Adrià
Gyori, Benjamin M. https://orcid.org/0000-0001-9439-5346
Hartung, Michael https://orcid.org/0000-0002-3992-0125
Hoyt, Charles Tapley
Klein, Christoph
Korcsmaros, Tamas https://orcid.org/0000-0003-1717-996X
Maier, Andreas https://orcid.org/0000-0003-4408-0068
Mann, Matthias https://orcid.org/0000-0003-1292-4799
Ochoa, David https://orcid.org/0000-0003-1857-278X
Pareja-Lorente, Elena
Popp, Ferdinand https://orcid.org/0000-0003-3833-5052
Preusse, Martin https://orcid.org/0000-0003-4789-0592
Probul, Niklas https://orcid.org/0000-0002-5793-0626
Schwikowski, Benno
Sen, Bünyamin https://orcid.org/0000-0002-0853-4731
Strauss, Maximilian T. https://orcid.org/0000-0003-3320-6833
Turei, Denes
Ulusoy, Erva https://orcid.org/0000-0002-2643-0362
Waltemath, Dagmar
Wodke, Judith A. H.
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Article History
First Online: 19 June 2023
Competing interests
: J.S.-R. reports funding from GSK, Pfizer and Sanofi and fees from Travere Therapeutics and Astex Pharmaceuticals.